**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 68759

**Manuscript Type:** CASE REPORT

**Multiple endocrine neoplasia type 1 combined with thyroid neoplasm: A case report and review of literatures**

Xu JL *et al*. MEN 1 with PTC and nodular goiter

Jia-Lu Xu, Su Dong, Le-Le Sun, Jin-Xin Zhu, Jia Liu

**Jia-Lu Xu, Le-Le Sun, Jin-Xin Zhu,** Department ofThyroid Surgery, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Su Dong,** Department of Anesthesia, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China

**Jia Liu,** Department of Thyroid Surgery, The First Hospital of Jilin University, Changchun 130012, Jilin Province, China

**Author contributions:** Liu J and Xu JL performed the surgery, reviewed the literature and contributed to manuscript drafting; Dong S reviewed the literature and was responsible for the revision of the manuscript for important intellectual content; Sun LL and Zhu JX analyzed and interpreted the imaging findings; all authors issued final approval for the version to be submitted.

**Corresponding author: Jia Liu, MD, PhD, Surgeon,** Department of Thyroid Surgery, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130012, Jilin Province, China. liu\_jia@jlu.edu.cn

**Received:** June 3, 2021

**Revised:** July 7, 2021

**Accepted: December 22, 2021**

**Published online:**

**Abstract**

BACKGROUND

Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumor syndrome inherited in an autosomal dominant manner and presents mostly as parathyroid, endocrine pancreas (such as gastrinoma) and anterior pituitary tumors. At present, papillary thyroid carcinoma (PTC) and nodular goiter are not regarded as components of MEN1.

CASE SUMMARY

A 35-year-old woman presented with MEN1 accompanied by coinstantaneous PTC and nodular goiter. The pathological diagnosis was PTC with cervical lymph node metastasis, nodular goiter, parathyroid cyst and adenomatoid hyperplasia. Genetic testing was performed and a *MEN1* gene mutation was detected. The patient underwent unilateral lobectomy of the thyroid gland and surgical removal of the parathyroid tumors. At 18 mo of follow-up, ultrasonic examination of the neck showed no abnormality. Serum calcium and parathyroid hormone levels were normal. No new MEN1-associated tumors were detected.

CONCLUSION

The role of inactivating mutations of *MEN1* gene in tumorigenesis of PTC and/or nodular goiter remains to be determined by more case reports and further research.

**Key Words:** Multiple endocrine neoplasia type 1; Thyroid cancer; Papillary thyroid carcinoma; Nodular goiter; Case report

Xu JL, Dong S, Sun LL, Zhu JX, Liu J. Multiple endocrine neoplasia type 1 combined with thyroid neoplasm: A case report and review of literatures. *World J Clin Cases* 2021; In press

**Core Tip:** Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumor syndrome inherited in an autosomal dominant manner and presents mostly as parathyroid, endocrine pancreas and anterior pituitary tumors. We here report a case of MEN1 combined with papillary thyroid carcinoma (PTC) and nodular goiter, and review the literature. The role of inactivating mutations of *MEN1* gene in tumorigenesis of PTC and/or nodular goiter is still controversial. There may be a potential correlation between MEN1 syndrome and papillary thyroid carcinoma/ nodular goiter.

**INTRODUCTION**

Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary tumor syndrome inherited in an autosomal dominant manner and characterized by a predisposition to a multitude of endocrine neoplasms, mostly of the parathyroid, endocrine pancreas and anterior pituitary tumors. Other endocrine tumors in MEN1 include gastroenteropancreatic neuroendocrine tumors, adrenocortical tumors, and rarely pheochromocytoma[1-3]. MEN1 is caused by inactivating mutations of *MEN1* gene. The incidence is 1/10000–1/100000. *MEN1* is a tumor suppressor gene and is located on human chromosome 11q13. *MEN1* gene is 9 kb and contains 10 exons. Exons 2–10 are coding regions. *MEN1* gene encodes the protein menin, which contains 610 amino acids[4,5]. Menin plays an important role in cell division and proliferation, cell cycle regulation and genomic stability. Mutations of *MEN1* gene can lead to functional loss of menin, and occurrence of multiple tumors[6-10]. Gene mutation analysis is an important diagnostic method for MEN1[1].

It has been reported that expression of menin is preserved in human normal thyroid tissue and thyroid tumors, but it can be decreased or absent in certain types of thyroid tumors[11-14]. Currently, little is known about the prevalence of papillary thyroid carcinoma (PTC) and nodular goiter in MEN1 patients, and it is unclear whether tumorigenesis of these thyroid tumors is MEN1 related. The role of menin protein deficiency in tumorigenesis of PTC and/or nodular goiter is still controversial. Here, we present a patient with MEN1 accompanied by coinstantaneous PTC and nodular goiter and review the related literature.

**CASE PRESENTATION**

***Chief complaints***

A 35-year-old woman presented with a neck mass on physical examination, but without abnormal feelings.

***History of present illness***

The patient immediately came to our hospital after discovery of the neck mass.

***History of past illness***

The patient underwent partial resection of the pancreas and stomach for pancreatic and gastroduodenal neuroendocrine tumor 4 years ago. The patient had a history of pituitary microadenoma for 2 years, which was not treated but under observation.

***Personal and family history***

Her father had a history of stomach surgery, but the details were unknown since he died 20 years ago. Other relatives of the patient had no symptoms of MEN1 syndrome.

***Physical examination***

Her father had a history of stomach surgery, but the details were unknown since he died 20 years ago. Other relatives of the patient had no symptoms of MEN1 syndrome.

There was an anterior neck mass which was movable due to breathing.

***Laboratory examinations***

The results of biochemical tests were as follows: serum calcium 2.82 mmol/L (reference range: 2.11–2.52 mmol/L); albumin 47.7 g/L (reference range: 40–55 g/L); serum intact parathyroid hormone (iPTH) elevated to 676.3 pg/mL (reference range: 12–88 pg/mL); gastrin 17: 0.8 pmol/L (reference range: 1–15 pmol/L); thyroid function was normal; thyroid peroxidase antibody was 23.98 IU/mL (reference range: < 35 IU/mL).

***Imaging examinations***

Neck ultrasound revealed a 64 mm × 28 mm × 45 mm cystic mass located below the right lobe of the thyroid gland with a well-defined smooth border, and several solid nodules were detected in the right thyroid lobe, with the largest (18 mm × 10 mm × 8 mm) in the right lower thyroid lobe. The largest nodule in the thyroid had an unclear boundary, dotted calcification and abundant internal blood flow (Figure 1A and B). Computed tomography (CT) or magnetic resonance imaging examination showed changes in the pituitary region; lesions in the right thyroid lobe and superior mediastinum; and changes after partial gastrectomy and in the tail of the pancreas (Figure 2A–D). In 99mTc-methoxyisobutyl isonitrile scintigraphy, tracer uptake was increased in the right lower region of the thyroid gland and mediastinum, and no abnormal retention of the tracer in the late phase was observed. No uptake was detected in other regions. Preoperative sestamibi single-photon emission computed tomography (SPECT)/CT found a lesion in the right lower thyroid lobe and part of which extended to the superior mediastinum (Figure 3A). Bone scanning showed T-scores -2.6 and Z-scores -2.0.

**FINAL DIAGNOSIS**

The final diagnosis of the presented case was thyroid neoplasm (right lobe).

**TREATMENT**

Because the patient had a large functional parathyroid cyst, her serum calcium and iPTH levels were significantly abnormal and several solid nodules were detected in the right thyroid lobe (the largest nodule was suspected to be malignant by ultrasound). Fine needle aspiration (FNA) could not be performed for parathyroid cysts. And the patient refused FNA of the thyroid nodule before operation for fear of additional injury and requested to perform rapid intraoperative pathological diagnosis. Parathyroidectomy and unilateral thyroid lobectomy were recommended and performed with the patient’s consent.

During the operation, gross examination of the largest cyst showed that it was partially surrounded and contiguous with the right lower thyroid lobe and extended to the superior mediastinum, and it was peeled off easily from the right lower thyroid lobe and mediastinum. Furthermore, it was filled with clear watery fluid, suggesting that it was a parathyroid cyst (Figure 3B). The largest cyst and right lobe of the thyroid were removed. The central lymph nodes were cleared. Intraoperative frozen section pathology showed that the largest cyst was the source of parathyroid, and parathyroid carcinoma was excluded. A PTC (maximum diameter 1 cm, invading the capsule) was found in the thyroid right lobe. In the central lymph nodes, 4/5 had cancer metastasis. iPTH at 20 min after resection was decreased to 253.4 pg/mL. Other parathyroid glands were explored. Two upper parathyroid glands were normal. The left lower parathyroid was enlarged and removed. Rapid intraoperative pathological examination revealed that the left lower parathyroid had adenomatoid hyperplasia. After another 20 min, serum iPTH decreased to 63.9 pg/mL. The postoperative pathological results were PTC (maximum diameter 1cm, invading the capsule) in the right thyroid lobe and nodular goiter. In the central lymph nodes, 4/5 had PTC metastasis. In the right cervical cysts, parathyroid cysts (monolocular) showed adenomatous hyperplasia. In the left lower parathyroid, adenomatous hyperplasia was observed (Figure 4). The patient had indications for a total thyroidectomy because of central compartment lymph node metastasis. But the patient had a strong desire to preserve the thyroid gland and refused to remove the left lobe.

After surgery, the patient was closely monitored on serum calcium and was pumped calcium gluconate 2.0 g/day through a central venous catheter for 5 d. After taking 1.5 g calcium carbonate daily for 3 mo, her serum calcium levels returned to normal. Meanwhile the patient received endocrine suppression therapy after the operation.

**OUTCOME AND FOLLOW-UP**

After the operation, genetic analysis was performed, and a germline *MEN1* gene mutation was detected. There was a heterozygous mutation in the second exon of *MEN1* gene which was 357-360delCTGT. During follow-up, there was no hypoparathyroidism or other complications. The laboratory data on postoperative day 2 showed that serum calcium was 1.98 mmol/L and iPTH was 24.1 pg/mL. After taking 1.5 g calcium carbonate daily for 3 mo, the patient’s laboratory data improved: calcium 1.98 mmol/L and iPTH 43.7 pg/mL. Calcium was 2.47 mmol/L and iPTH was 61 pg/mL after 18 mo. One month after the operation, the dose of levothyroxine was reduced from 75 mg to 50 mg.

**DISCUSSION**

Currently, the role of inactivating mutations of *MEN1* gene in tumorigenesis of PTC and/or nodular goiter is still controversial. It remains to be determined by more case reports and further research.

MEN1 is a rare hereditary tumor syndrome inherited in an autosomal dominant manner and presents mostly as the parathyroid[15], endocrine pancreas (such as gastrinoma)[16] and anterior pituitary tumors[17]. Other endocrine and nonendocrine lesions of MEN1, such as adrenal cortical tumors, carcinoids of the bronchi, gastrointestinal tract and thymus lipomas, angiofibromas, and collagenomas, have also been described[1,18]. MEN1 with a large functioning parathyroid cyst is rare. Cavalli *et al*[15] found that approximately 300 cases of sporadic parathyroid cysts had been reported up to 2017, and only two cases have been described in MEN1. Parathyroid cysts can be divided into functioning and nonfunctioning, and most parathyroid cysts are nonfunctioning. The functioning parathyroid cysts are more likely to be caused by degenerative changes in parathyroid adenoma than hyperplasia in our case[19]. In many cases, it is difficult to diagnose the nature of the cyst merely by ultrasound before surgery. Parathyroid cysts need to be differentiated from lymphatic cysts, cystic thyroid nodules and hemangioma[20,21]. The diagnostic rate can be improved by laboratory examination and other imaging examinations. Preoperative SPECT/CT is useful in localizing parathyroid cysts in most patients, with an accuracy rate up to 79% if it is interpreted in combination with cervical ultrasound images[22]. Postoperative pathological diagnosis is the gold standard. The clinical features of hyperparathyroidism (HPT) with MEN1 are similar to those with sporadic HPT, but the former is often more aggressive. For patients who have HPT with MEN1, early surgical treatment is preferred. Surgical treatment should be considered in asymptomatic patients when (1) serum calcium is higher than the reference range 2.52mmol/L; (2) glomerular filtration < 60 mL/min; (3) bone mineral density at any point is 2.5 or lower, or patient has fragility fractures; and (4) age < 50 years. Whether early surgery can reduce the incidence rate and mortality is not clear. For patients who have HPT with MEN1, especially in asymptomatic or mild and young patients, early parathyroidectomy can reduce the long-term effects of HPT on the patients, especially reducing the bone loss. Although our case was a young woman with normal upper parathyroid glands on both sides, and bilateral lower parathyroid glands showed adenoma-like changes and hyperplasia, parathyroid hormone and serum calcium levels had increased significantly. To avoid a permanent hypoparathyroidism, we did not perform subtotal parathyroidectomy or a total parathyroidectomy with parathyroid tissue autotransplantation. And based on our past experience, unless it is a parathyroid cancer, surgery can achieve a better treatment effect by removing the problematic parathyroid glands. In the present case, the parathyroid hormone had decreased from 676.3 pg/mL to 63.9 pg/mL after the removal of the bilateral inferior parathyroid glands, and the patient’s serum parathyroid hormone was 47.6 pg/mL at 27 mo postoperatively. FNA is the most useful means for diagnosis of thyroid nodules, however, it is not widely accepted for diagnosis of parathyroid tumors due to the risk of dissemination of tumor cells.

Two different forms of MEN1, sporadic and familial, have been described[23]. The sporadic form presents with two of the three principal MEN1-related endocrine tumors (parathyroid adenoma, enteropancreatic tumor and pituitary tumor) within a single patient, while the familial form consists of MEN1 with at least one first-degree relative showing one of the endocrine characteristic tumors[24-27]. In our case, the patient did not provide a clear family history. It is still unclear what form of MEN1 our patient had. There is no evidence to exclude the accidental occurrence of MEN1 with PTC and nodular goiter in this patient.

So far, few cases of thyroid carcinoma and/or nodular goiter combined with MEN1 have been reported. Whether there is a correlation among them is still controversial[12,28,29]. Hill *et al*[30] investigated the probability of concomitant thyroid cancer in patients with MEN1. They found that in patients with MEN1, a 28% substantial incidence of thyroid cancer was observed and all cancers in MEN1 patients were common PTCs histologically (100%). We noticed that only PTCs that measured >1 cm in diameter were considered in the report by Hill *et al*[30]. But at present, papillary thyroid microcarcinoma (PTMC) accounts for more than half of all PTCs in clinical practice. If we take these PTMC cases into account, the actual incidence of papillary thyroid carcinoma would be higher in MEN1 patients. Our case was PTMC. MEN1 is caused by inactivating mutations of the *MEN1* gene that encodes the protein menin[2]. Menin is a nuclear protein whose interaction with several other nuclear proteins indicates a role in transcriptional regulation. Previous studies have supported a role for MEN1 in controlling cell growth and differentiation, and in sensing or repairing DNA damage as well. The loss of menin function in tumor precursor cells is involved in the mechanism underlying tumor formation in MEN1[8-10,31-33]. Research showed that the inactivation of menin in the thyroid gland of young mice affected the proliferation of follicular cells[13]. Capraru *et al*[11] showed that the expression of menin was positive, identical to normal thyroid tissue, but it could be decreased or absent in some thyroid tumors including PTC. As is well known, mutations of the *MEN1* gene cause deficiency in the menin protein in MEN1 patients. There was a heterozygous 357-360delCTGT mutation in the second exon of MEN1 gene in our case. Further molecular studies are needed to evaluate the role of menin protein deficiency in tumorigenesis of PTC and nodular goiter. Kazubskaia *et al*[34] investigated follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance and molecular diagnostic markers. They believed that familial PTC and PTC may be a component of multitumor syndromes, such as MEN1, Cowden syndrome, and familial adenomatous polyposis. We speculate upon possible reasons for the association between MEN1 and PTC/nodular goiter. Loss of heterozygosity (LOH) studies have been used to identify sites harboring tumor suppressor genes involved in tumor initiation or progression. *MEN1* is a tumor suppressor gene located on human chromosome 11q13. Speciﬁc genomic areas, such as 3p22, 7q31, 11q13 and 11q23, have been reported to be involved in some epithelial or endocrine tumor types[35]. PTC is also one of the endocrine tumors. Whether inactivating mutations of 11q13 can induce PTC remains to be further studied. Chu *et al*[36,37] found MEN1 deletion in neurotrophic tyrosine kinase receptor (NTRK)-rearranged PTC patients. They also proved that nucleotide variants and indels in pTERT, MEN1 and CDH1 were observed in several kinase fusion-related PTCs. The relationship among MEN1, PTC and NTRK needs to be further studied. In the analysis of *MEN1* gene, about 20% may have false negative results due to the diversity of the causative mutation and scattered position in the entire open reading frame. Moreover, approximately 10% new germline mutations are being detected in the overall MEN1 patients, which may be the reason why the genotype- phenotype correlations could not be identical in 10%-30% of patients[38]. In 2008, Kim *et al*[29] reported the first case of PTC combined with MEN1 in Korea. Their patient’s genetic analysis of DNA had revealed no germline mutation in *MEN1* gene locus. But there was a genetic mutation in our case. Menin, the protein encoded by *MEN1* gene is ubiquitously expressed in endocrine tissues, is less in many endocrine tumors including PTC. Deletion of the MEN1 tumor suppression still might be etiologically related to the oncogenesis of PTC. DNA analysis of more samples with PTC combined with MEN1 may be helpful. Now it is very difficult to confirm the LOH of *MEN1* gene completely and accurately, which has dozens of polymorphic markers[29]. The clinical aspects and molecular genetics of MEN1 were reviewed together with the reported 1336 mutations[39]. It has been proved that many of the diseases that have been widely believed to be associated with MEN1 mutations, such as pituitary tumors, lung carcinoids, *etc.*, sometimes failed to exhibit meaningful LOH at 11q13[40]. For PTC, some people have used three of polymorphic markers to test one patient’s sample, with limited results[12]. The exact significance remains to be determined by more case reports and further research. It is another possibility that MEN1 patients who develop PTC may have specific *MEN1* mutations of the affected allele that act like dominant oncogenes with regard to thyroid cancer oncogenesis. If any of these scenarios was the case, the *MEN1* gene could play a role in the development of the papillary cancer without obvious LOH of the gene locus.

**CONCLUSION**

In summary, we presented a rare case of MEN1 combined with PTC and nodular goiter, in which a germline mutation of the *MEN1* gene was detected. It is possible there is a potential correlation between MEN1 syndrome and PTC/nodular goiter. However, further studies and additional case reports are required to clarify it.

**REFERENCES**

1 **Marini F**, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, Brandi ML. Multiple endocrine neoplasia type 1. *Orphanet J Rare Dis* 2006; **1**: 38 [PMID: 17014705 DOI: 10.1186/1750-1172-1-38]

2 **Kamilaris CDC**, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. *Front Endocrinol (Lausanne)* 2019; **10**: 339 [PMID: 31263451 DOI: 10.3389/fendo.2019.00339]

3 **Giudici F**, Cavalli T, Giusti F, Gronchi G, Batignani G, Tonelli F, Brandi ML. Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up. *World J Surg* 2017; **41**: 2312-2323 [PMID: 28429092 DOI: 10.1007/s00268-017-4019-2]

4 **Shi J**, Gao Z, Gao J, Li G, Chen Y. Predictors and outcome surgery for posterior cortex epilepsies. *Clin Neurol Neurosurg* 2018; **171**: 124-128 [PMID: 29909183 DOI: 10.1016/j.clineuro.2018.06.003]

5 **Tsukada T**, Nagamura Y, Ohkura N. MEN1 gene and its mutations: basic and clinical implications. *Cancer Sci* 2009; **100**: 209-215 [PMID: 19068082 DOI: 10.1111/j.1349-7006.2008.01034.x]

6 **Marx SJ**. Recent Topics Around Multiple Endocrine Neoplasia Type 1. *J Clin Endocrinol Metab* 2018; **103**: 1296-1301 [PMID: 29897580 DOI: 10.1210/jc.2017-02340]

7 **Suzuki J**, Yamada T, Inoue K, Nabe S, Kuwahara M, Takemori N, Takemori A, Matsuda S, Kanoh M, Imai Y, Yasukawa M, Yamashita M. The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation. *Nat Commun* 2018; **9**: 3296 [PMID: 30120246 DOI: 10.1038/s41467-018-05854-6]

8 **Li JWY**, Hua X, Reidy-Lagunes D, Untch BR. MENIN loss as a tissue-specific driver of tumorigenesis. *Mol Cell Endocrinol* 2018; **469**: 98-106 [PMID: 28965973 DOI: 10.1016/j.mce.2017.09.032]

9 **Cheng P**, Li G, Yang SS, Liu R, Jin G, Zhou XY, Hu XG. Tumor suppressor Menin acts as a corepressor of LXRα to inhibit hepatic lipogenesis. *FEBS Lett* 2015; **589**: 3079-3084 [PMID: 25962847 DOI: 10.1016/j.febslet.2015.04.049]

10 **Dreijerink KMA**, Groner AC, Vos ESM, Font-Tello A, Gu L, Chi D, Reyes J, Cook J, Lim E, Lin CY, de Laat W, Rao PK, Long HW, Brown M. Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. *Cell Rep* 2017; **18**: 2359-2372 [PMID: 28273452 DOI: 10.1016/j.celrep.2017.02.025]

11 **Capraru OM**, Decaussin-Petrucci M, Joly MO, Borda A, Fanfaret IS, Borson-Chazot F, Selmi-Ruby S. EXPRESSION OF MENIN IN THE HUMAN THYROID GLAND. *Acta Endocrinol (Buchar)* 2017; **13**: 154-160 [PMID: 31149167 DOI: 10.4183/aeb.2017.154]

12 **Desai D**, McPherson LA, Higgins JP, Weigel RJ. Genetic analysis of a papillary thyroid carcinoma in a patient with MEN1. *Ann Surg Oncol* 2001; **8**: 342-346 [PMID: 11352308 DOI: 10.1007/s10434-001-0342-8]

13 **Căpraru OM**, Berger N, Gadot N, Decaussin-Petrucci M, Zhang C, Borda A, Szilágyi T, Borson-Chazot F, Selmi-Ruby S. Histopathological changes induced by selective inactivation of menin on the thyroid gland in RET÷PTC3 and E7 transgenic mice. A study of 77 cases. *Rom J Morphol Embryol* 2016; **57**: 91-98 [PMID: 27151693]

14 **Lodewijk L**, Bongers PJ, Kist JW, Conemans EB, de Laat JM, Pieterman CR, van der Horst-Schrivers AN, Jorna C, Hermus AR, Dekkers OM, de Herder WW, Drent ML, Bisschop PH, Havekes B, Rinkes IH, Vriens MR, Valk GD. Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. *Eur J Endocrinol* 2015; **172**: 337-342 [PMID: 25572387 DOI: 10.1530/EJE-14-0897]

15 **Cavalli T**, Giudici F, Nesi G, Amorosi A, Santi R, Brandi ML, Tonelli F. Cystic parathyroid glands in MEN1: A rare entity? *Fam Cancer* 2017; **16**: 249-256 [PMID: 27766445 DOI: 10.1007/s10689-016-9936-y]

16 **Ito T**, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. *Medicine (Baltimore)* 2013; **92**: 135-181 [PMID: 23645327 DOI: 10.1097/MD.0b013e3182954af1]

17 **Delemer B**. MEN1 and pituitary adenomas. *Ann Endocrinol (Paris)* 2012; **73**: 59-61 [PMID: 22542456 DOI: 10.1016/j.ando.2012.03.038]

18 **Carroll RW**. Multiple endocrine neoplasia type 1 (MEN1). *Asia Pac J Clin Oncol* 2013; **9**: 297-309 [PMID: 23279763 DOI: 10.1111/ajco.12046]

19 **Tamiya H**, Miyakawa M, Suzuki H, Takeshita A, Ohashi K, Usui T, Miura D, Takeuchi Y. A large functioning parathyroid cyst in a patient with multiple endocrine neoplasia type 1. *Endocr J* 2013; **60**: 709-714 [PMID: 23386389 DOI: 10.1507/endocrj.ej12-0306]

20 **Papavramidis TS**, Chorti A, Pliakos I, Panidis S, Michalopoulos A. Parathyroid cysts: A review of 359 patients reported in the international literature. *Medicine (Baltimore)* 2018; **97**: e11399 [PMID: 29995785 DOI: 10.1097/MD.0000000000011399]

21 **Arduc A**, Tutuncu YA, Dogan BA, Arikan Ileri AB, Tuna MM, Ozcan HN, Isik S, Berker D, Guler S. Parathyroid cysts. *Am Surg* 2015; **81**: E163-E165 [PMID: 25831166]

22 **Johnson NA**, Yip L, Tublin ME. Cystic parathyroid adenoma: sonographic features and correlation with 99mTc-sestamibi SPECT findings. *AJR Am J Roentgenol* 2010; **195**: 1385-1390 [PMID: 21098199 DOI: 10.2214/AJR.10.4472]

23 **Makri A**, Bonella MB, Keil MF, Hernandez-Ramirez L, Paluch G, Tirosh A, Saldarriaga C, Chittiboina P, Marx SJ, Stratakis CA, Lodish M. Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease. *Clin Endocrinol (Oxf)* 2018; **89**: 437-443 [PMID: 29927501 DOI: 10.1111/cen.13796]

24 **Hendy GN**, Cole DE. Genetic defects associated with familial and sporadic hyperparathyroidism. *Front Horm Res* 2013; **41**: 149-165 [PMID: 23652676 DOI: 10.1159/000345675]

25 **Beijers HJBH**, Stikkelbroeck NML, Mensenkamp AR, Pfundt R, van der Luijt RB, Timmers HJLM, Hermus ARMM, Kempers MJE. Germline and somatic mosaicism in a family with multiple endocrine neoplasia type 1 (MEN1) syndrome. *Eur J Endocrinol* 2019; **180**: K15-K19 [PMID: 30481156 DOI: 10.1530/EJE-18-0778]

26 **Horvath A**, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. *Rev Endocr Metab Disord* 2008; **9**: 1-11 [PMID: 18200440 DOI: 10.1007/s11154-007-9066-9]

27 **Karges W**, Jostarndt K, Maier S, Flemming A, Weitz M, Wissmann A, Feldmann B, Dralle H, Wagner P, Boehm BO. Multiple endocrine neoplasia type 1 (MEN1) gene mutations in a subset of patients with sporadic and familial primary hyperparathyroidism target the coding sequence but spare the promoter region. *J Endocrinol* 2000; **166**: 1-9 [PMID: 10856877 DOI: 10.1677/joe.0.1660001]

28 **Kasaian K,** Chindris AM, Wiseman SM, Mungall KL, Zeng T, Tse K, Schein JE, Rivera M, Necela BM, Kachergus JM, Casler JD, Mungall AJ, Moore RA, Marra MA, Copland JA, Thompson EA, Smallridge RC, Jones SJ. MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma. *J Clin Endocrinol Metab* 2015; **100**: E611-615 [PMID: 25625803 DOI: 10.1210/jc.2014-3622]

29 **Kim HJ**, Park JS, Kim CS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, Ahn CW. A case of multiple endocrine neoplasia type 1 combined with papillary thyroid carcinoma. *Yonsei Med J* 2008; **49**: 503-506 [PMID: 18581603 DOI: 10.3349/ymj.2008.49.3.503]

30 **Hill KA**, Yip L, Carty SE, McCoy KL. Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. *Thyroid* 2019; **29**: 252-257 [PMID: 30608029 DOI: 10.1089/thy.2017.0675]

31 **Razmara M**, Monazzam A, Skogseid B. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration. *Cell Commun Signal* 2018; **16**: 64 [PMID: 30285764 DOI: 10.1186/s12964-018-0278-2]

32 **Dreijerink KMA**, Timmers HTM, Brown M. Twenty years of menin: emerging opportunities for restoration of transcriptional regulation in MEN1. *Endocr Relat Cancer* 2017; **24**: T135-T145 [PMID: 28811299 DOI: 10.1530/ERC-17-0281]

33 **Wu G**, Yuan M, Shen S, Ma X, Fang J, Zhu L, Sun L, Liu Z, He X, Huang, Li T, Li C, Wu J, Hu X, Li Z, Song L, Qu K, Zhang H, Gao P. Menin enhances c-Myc-mediated transcription to promote cancer progression. *Nat Commun* 2017; **8**: 15278 [PMID: 28474697 DOI: 10.1038/ncomms15278]

34 **Kazubskaia TP**, Kozlova VM, Kondrat'eva TT, Pavlovskaia AI, Marakhonov AV, Baranova AV, Ivanova NI, Stepanova AA, Poliakov AV, Belev NF, Brzhezovskiĭ VZh. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers]. *Arkh Patol* 2014; **76**: 3-12 [PMID: 25543402]

35 **Oriola J**, Halperin I, Mallofré C, Muntané J, Angel M, Rivera-Fillat F. Screening of selected genomic areas potentially involved in thyroid neoplasms. *Eur J Cancer* 2001; **37**: 2470-2474 [PMID: 11720845 DOI: 10.1016/s0959-8049(01)00302-1]

36 **Chu YH**, Dias-Santagata D, Farahani AA, Boyraz B, Faquin WC, Nosé V, Sadow PM. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC). *Mod Pathol* 2020; **33**: 2186-2197 [PMID: 32457407 DOI: 10.1038/s41379-020-0574-4]

37 **Chu YH**, Wirth LJ, Farahani AA, Nosé V, Faquin WC, Dias-Santagata D, Sadow PM. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. *Mod Pathol* 2020; **33**: 2458-2472 [PMID: 32737449 DOI: 10.1038/s41379-020-0638-5]

38 **Guru SC**, Manickam P, Crabtree JS, Olufemi SE, Agarwal SK, Debelenko LV. Identification and characterization of the multiple endocrine neoplasia type 1 (MEN1) gene. *J Intern Med* 1998; **243**: 433-439 [PMID: 9681840 DOI: 10.1046/j.1365-2796.1998.00346.x]

39 **Lemos MC**, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. *Hum Mutat* 2008; **29**: 22-32 [PMID: 17879353 DOI: 10.1002/humu.20605]

40 **Dong Q**, Debelenko LV, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC, Manickam P, Skarulis M, Lubensky IA, Liotta LA, Collins FS, Marx SJ, Spiegel AM. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. *J Clin Endocrinol Metab* 1997; **82**: 1416-1420 [PMID: 9141526 DOI: 10.1210/jcem.82.5.3944]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed

**Peer-review model:** Single blind

**Peer-review started:** June 3, 2021

**First decision:** June 25, 2021

**Article in press:**

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Casella C **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H


**Figure Legends**

****


**Figure 1 Thyroid ultrasonography.** A: Solid nodule with multiple punctate microcalcifications and relatively regular shape within the right lobe of the thyroid (white arrow); B: A huge cystic mass with a clear boundary located in the lower right lobe of the thyroid (white arrow).



**Figure 2** **Computed tomography/magnetic resonance imaging examination.** A: A lesion located in the right side of the trachea (white arrow); B: Enlarged pituitary structure (white arrow); C: Remnant stomach anastomosed to the jejunum (white arrow); D: Remnant pancreas body and tail (white arrow).



**Figure 3 Single-photon emission computed tomography/computed tomography and intraoperative findings.** A: Single-photon emission computed tomography/computed tomography revealed that a mass was located below the lower pole of the right thyroid lobe that was growing downward and protruding into the superior mediastinum. No significant radioactivity concentration was observed in the mass (white arrow); B: A large cyst was filled with clear watery fluid and contiguous with the lower right thyroid lobe (black arrow).



**Figure 4 Histopathological examinations.** A: Parathyroid cyst: a single locular cystic mass covered by a single layer of flattened transparent cells with small clusters of extruded parathyroid tissue in the wall; B: Thyroid papillary carcinoma: complex branching papilla with fibrous vascular center, and surface coated with simple columnar epithelium. The epithelial nuclei were ground-glass like, with nuclear grooves, intranuclear pseudo-inclusions, and nuclear overlap; C: Nodular goiter: the follicles vary in size and are filled with colloid; D: Metastatic lesions of thyroid papillary carcinoma in lymph nodes. Hematoxylin and eosin staining, 100× magnification.